Report of Foreign Issuer (6-k)
May 22 2019 - 6:10AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT
TO RULE 13a-16 or 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the month of May, 2019
Commission File Number: 001-38452
MEREO BIOPHARMA GROUP PLC
(Translation of registrant’s name
into English)
4
th
Floor, One Cavendish Place,
London, W1G 0QF, United Kingdom
(Address of principal executive office)
Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F
x
Form 40-F
¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
¨
Mereo BioPharma Group plc
("Mereo" or the "Company")
Notification of PDMR Dealing
London, May 22, 2019
- Mereo BioPharma
Group plc (AIM: MPH, NASDAQ: MREO), a clinical stage UK based biopharmaceutical company focused on rare diseases, received notification
that on May 20, 2019, Alexandra (“Wills”) Hughes-Wilson, Head of Patient Access & Commercial Planning at Mereo,
purchased 1,650 American Depositary Shares (ADSs) at a price of USD5.42 per share.
The below announcement and notification
is made in accordance with the EU Market Abuse Regulation. The form required under the EU Market Abuse Regulation follows.
1
|
Details of the person discharging managerial responsibilities
|
a)
|
Name
|
Alexandra (“Wills”) Hughes-Wilson
|
2
|
Reason for the notification
|
a)
|
Position/status
|
Head of Patient Access & Commercial Planning, Mereo BioPharma Group plc
|
b)
|
Initial notification/ Amendment
|
Initial notification
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
a)
|
Name
|
Mereo BioPharma Group plc
|
b)
|
LEI
|
213800U8JQHIJOS5AS09
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
a)
|
Description of the financial instrument, type of instrument and identification code
|
MEREO BIOPHARMA GROUP PLC AMERICAN DEPOSITARY SHARES (ADSs)
|
b)
|
Nature of the transaction
|
PURCHASE of ADSs
|
|
|
|
|
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
USD5.42
|
1,650
|
|
|
|
|
|
|
|
d)
|
Aggregated information: volume, Price
|
Aggregated volume: 1,650
Aggregated price: USD5.42
|
e)
|
Date of the transaction
|
2019-05-20
|
f)
|
Place of the transaction
|
XNMS
|
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
Date: May 22, 2019
|
MEREO BIOPHARMA GROUP PLC
|
|
|
|
|
|
|
|
By:
|
/s/ Charles Sermon
|
|
|
Name: Charles Sermon
|
|
|
Title: General Counsel
|
Mereo BioPharma (NASDAQ:MREO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mereo BioPharma (NASDAQ:MREO)
Historical Stock Chart
From Apr 2023 to Apr 2024